mozavaptan has been researched along with ARPKD in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
| Branden, MG; Gattone, VH; Maser, RL; Rosenberg, JM; Tian, C | 1 |
2 other study(ies) available for mozavaptan and ARPKD
| Article | Year |
|---|---|
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |
Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
Topics: Aldehyde Reductase; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporin 3; Aquaporin 6; Aquaporins; Benzazepines; Female; Gene Expression Regulation, Developmental; Kidney Concentrating Ability; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Polycystic Kidney, Autosomal Recessive; Receptors, Vasopressin; RNA, Messenger | 1999 |